|
|
|
|
|
|
最高研发阶段临床2期 |
首次获批国家/地区- |
首次获批日期- |
A Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CBP-201 Administered to Healthy Adult Subjects
A Phase I, Multicenter, Randomized, Double-blind, Double-dummy, Placebo- and Positive-Controlled Study to Investigate the Effects of CBP-307 on the QTc Interval in Healthy Subjects
This study will investigate the effects of therapeutic and supratherapeutic oral doses of CBP-307 on the QTc interval in healthy subjects.
A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study in Healthy Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics of CBP-174 After Oral Administration
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of CBP-174 after a single oral dose in healthy adult subjects.
100 项与 Connect Biopharma Australia Pty Ltd. 相关的临床结果
0 项与 Connect Biopharma Australia Pty Ltd. 相关的专利(医药)
100 项与 Connect Biopharma Australia Pty Ltd. 相关的药物交易
100 项与 Connect Biopharma Australia Pty Ltd. 相关的转化医学